Background Low troponin concentrations have been shown to be informative in the prognosis of acute coronary syndrome. We have investigated the analytical performance of four commonly used cardiac troponin I methods at concentrations approaching their analytical limit of detection.
Introduction
There have recently been a series of published clinical trials showing that, in patients with acute coronary syndrome, low concentrations of troponin, approaching the limit of detection (LOD), are informative for predicting adverse outcomes. 1--9 Assays with superior analytical sensitivity, such as the Beckman AccuTnI assay, are able to identify those persons with acute coronary syndrome who are at clinical risk for an adverse outcome. 3 The European Society of Cardiology/American College of Cardiology (ESC/ACC) recommend that an elevated troponin concentration be de¢ned as one which is greater than the 99th percentile of the upper reference limit, with a coe⁄cient of variation (CV) of 10% at this concentration. 10 Not all troponin assays perform equally well at low troponin concentrations. It is therefore valuable to know the analytical performance of the various troponin assays at concentrations approaching the LOD.
We have therefore performed a study, looking at the comparative analytical performance of four di¡erent troponin assays at concentrations corresponding to these assays' LODs, 20% and 10% CV.
Materials and methods
A total of 167 patient samples collected into lithiumheparin (Greiner Bio-One,Vacuette LH Lithium-Heparin Sep) were selected from all patient requests over a twoweek period for troponin I (TnI) at the Prince Charles Hospital in Brisbane, which is a specialist cardiac hospital. Patients were not required to have evidence of acute coronary syndrome, but were excluded if a troponin value of 42.1 mg/L was obtained by the Dade Behring Dimension RxL assay.
Samples were centrifuged at 3000 g for 10 min prior to analysis. Samples were analysed in singlicate within 24 h of collection on the Dade Behring Dimension RxL, Beckman Coulter Access 2, Abbott AxSYM, and Bayer Centaur for TnI. Each method was performed according to the manufacturer's guidelines.Where necessary, samples were stored and transported at 4 1C prior to analysis.
Technical information regarding the troponin assays under investigation is detailed in Table 1 .
The LOD was calculated as the mean plus 3 SD, as determined by assaying a 'normal' donor plasma 10 times. The concentration at which CVs of 20% and 10% were not exceeded was determined by preparing a series of dilutions of a single plasma sample from a patient known to have had a myocardial infarction, in a single normal donor plasma, and assayed over a 7 to 21-day period (n ¼ 20). These dilutions were stored frozen at --701C until analysis. All patients' samples were assayed in singlicate in each assay and assigned to a group based on analytical performance as described above.
Results
The precision pro¢les of the four troponin I assays are shown in Figure 1 , demonstrating the greater precision of the Beckman AccuTnI assay. The data obtained for LOD, 10% and 20% CVare shown in Table 2 and are similar to those found in the manufacturer's guidelines.
In Table 3 we show the relative analytical performance of these di¡erent assays with regard to their ability to detect troponin at concentrations relating to the CV of the individual assay. The TnI assays from Beckman and Dade had a greater proportion of positive results using the LOD as the threshold and, at concentrations corresponding to a CV of 10%, the detection rate for the Abbott assay was similar. At all concentrations, the detection rate for the Bayer assay was lower. Table 3 also shows the Passing--Bablok correlation (r 2 ) between the individual assays using the Access TnI assay as the standard. Although all the TnI assays are highly correlated with the Access TnI assay, there were individual patient samples that gave quite discordant results.
In Table 4 , we show the relative e⁄ciencies of the different assays in detecting troponin concentrations at di¡erent possible cutpoints, compared with the AccuT-nI assay. Using the LOD as the cut-o¡ point the AccuTnI has a far superior performance to any of the other assays, but at a concentration corresponding to a 20% CV the Dade TnI assay has a similar performance.
In Figure 2 , we provide this data in truncated graphical format so that individual discordances can be appreciated at these low troponin concentrations. In some cases, each point may represent more than one data value.
Discussion
The evidence from recent clinical trials has shown that in the setting of coronary artery ischaemia, any detectable cardiac troponin is associated with a worsened prognosis. 3--7 Thus, it is important to know the characteristics of di¡erent troponin assays at low concentrations. Further, it has been shown that of current, commercially available assays, the AccuTnI assay has proven of the greatest value in terms of identifying patients at risk of subsequent adverse events. 3 Because the clinical correlates have already been shown, our current study was designed simply to compare the analytical performances of the di¡erent assays. Of the four assays compared, the AccuTnI was the most e⁄cient at extremely low concentrations, while as concentrations approached 10% CV most assays performed similarly, though the Bayer Centaur assay had a markedly lower e⁄ciency of detection at all cutpoints examined. The current recommendations from the ESC/ACC are that an elevated troponin concentration be de¢ned as one which is greater than the 99th percentile of the upper reference limit, with a CV of 10% at this concentration. 10 No troponin assay currently meets these criteria. 11--13 There are problems with both elements of this proposal.
Clearly, the more precise an assay is, the more con¢dence there will be in using that result in a diagnostic setting. Thus, the goal of a 10% CV for cardiac troponin assays is laudable. However, laboratory results are generated to help clinical decision-making and there is now a wealth of evidence from clinical trials that very low troponin concentrations, down to the LOD, are informative for adverse clinical outcomes. Thus the technical wish for very precise data is discordant with clinical needs.
At present, data on the 99th population percentile are quite unreliable. Consider the two largest population studies using cardiac troponin. Muller-Bardorf et al. 14 studied 4955 people using the second-generation TnT assay from Roche and found the 99th population percentile was 0.06 mg/L, ¢ve times the detection limit of the assay. The second largest population study of 1951 people by Roche Diagnostics used the third generation TnT assay, and found that the 99th population percentile was below the LOD. Thus, a small improvement in the same assay has led to a dramatic change in the apparent 99th population percentile. Our own studies have shown that the Bayer Centaur TnI zero calibrator provides a higher signal than does healthy patients' plasma (Tate, unpublished). Thus, inadequacies in assay formulation at very low concentrations makes 99th percentile population data of little value at the present time. It is also worth noting that approximately 20% of people experiencing cardiac ischaemia do not experience pain. 15 There may therefore be a case for following up patients used to de¢ne a healthy population with regard to troponin inorder to ensure that they are indeed healthy.
How then should troponin concentration be reported? For the reason outlined above, using the 10% CV misses clinically important cases and the 99th population percentile cannot be reliably de¢ned at the present time due to assay limitations.
While the LOD appears to be the clinically important threshold in terms of identifying persons at risk of adverse outcomes, it would appear to be unsafe to try to report to this concentration, both because of day-today variability in assay precision and also because of the poor calibration of assays at low troponin concentrations, as described above.
This would appear to leave the common sense, pragmatic alternative of reporting down to a concentration corresponding to a 20% CV --the functional sensitivity. This has been the de facto standard in immunoassay for 15 years 16 and is the procedure in our own laboratories. 17 It is widely agreed that low concentrations of troponin are becoming more important in assessing patients with the acute coronary syndrome. Some assays have a greater ability to detect clinically signi¢cant changes in troponin concentrations; 3 it is therefore necessary to know about relative assay performance at these concentrations. We have investigated the performance of several commonly used assays at these low concentrations and found that the newer or recently modi¢ed assays, such as the Beckman Coulter AccuTnI and Dade Behring assays, are best able to identify low concentrations of troponin. These data and the results from recent clinical trials demonstrate that manufacturers must optimize their assays for dealing with very low concentrations of troponin. 
